Search

Displaying results 4041 - 4050 of 6835 in total
  1. Drug

    MBT-0312

    go.drugbank.com/drugs/DB05880
    Experimental

    MediGene's newly acquired drug candidates MBT-0312 aim at a novel method of cancer therapy by "starving out" tumors.

  2. Drug

    Anti-inhibitor coagulant complex

    go.drugbank.com/drugs/DB13151
    ApprovedInvestigational

    It is used to control bleeding in hemophilia A and B patients with inhibitors.

  3. Drug

    Brifentanil

    go.drugbank.com/drugs/DB09172
    ExperimentalIllicit

    The effects of brifentanil are very similar to those of alfentanil, with strong but short lasting analgesia and sedation, and particularly notable itching and respiratory depression.

  4. Drug

    Taspoglutide

    go.drugbank.com/drugs/DB14027
    Investigational

    In September 2010 Roche halted Phase III clinical trials due to incidences of serious hypersensitivity reactions and gastrointestinal side effects. As of May 2013 no new trials had been registered. … Taspoglutide is a pharmaceutical drug, a glucagon-like peptide-1 agonist (GLP-1 agonist), under investigation for treatment of type 2 diabetes being codeveloped by Ipsen and Roche.

  5. Drug

    Ombitasvir

    go.drugbank.com/drugs/DB09296
    ApprovedInvestigational

    Ombitasvir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). … The barrier for develoment of resistance to NS5A inhibitors is lower than that of NS5B inhibitors, another class of DAAs [A19593].

  6. Drug

    XL765

    go.drugbank.com/drugs/DB05241
    Investigational

    It is being developed by Exelixis, Inc. … XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR).

  7. Drug

    TD-2749

    go.drugbank.com/drugs/DB05905
    Experimental

    TD-2749 is selective 5-HT4 agonists discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders

  8. Drug

    Lumiliximab

    go.drugbank.com/drugs/DB06162
    Investigational

    Results published from the CLL clinical trial failed to meet primary endpoints. … Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007.

  9. Drug

    SCIB1

    go.drugbank.com/drugs/DB18439
    Investigational

    It consists of plasmid DNA molecules that express a modified antibody in human cells, working to stimulate the patient's T cells to have a stronger reaction against melanoma cells. … SCIB1 is an investigational cancer vaccine being developed by Scancell Ltd. It is being investigated for the treatment of melanoma.

  10. Drug

    Carbon black

    go.drugbank.com/drugs/DB11980
    Investigational

    [A263401] Upon inhalation, carbon black has been reported to trigger an inflammatory response in the lung tissue [A263401] and has been linked to carcinogenicity.[A263406, A263411, A263416] … Produced by the incomplete combustion of hydrocarbons, carbon black is an insoluble pigment [A263396] with demonstrated adverse effects on pulmonary function.

    Synonyms: DC BLACK NO. 2, D&C black no. 2